Childhood cancer in Peru poses a significant public health challenge, with a survival rate of 63.7%. Early detection, crucial for improving this rate, is hindered by access issues and late diagnoses. Symptoms such as persistent fever and abnormal lymph nodes require prompt identification. In 2018, the WHO, in collaboration with St. Jude Children's Research Hospital and the International Society of Paediatric Oncology, launched the Global Initiative for Childhood Cancer, aiming for a 60% survival rate by 2030. Peru, designated as a focal country in 2019, has implemented the CURE ALL technical package, focusing on centers of excellence, universal coverage, treatment regimens, and continuous evaluation. Despite advancements in infrastructure and training, challenges remain. The centralization of services in Lima complicates access for rural regions, and the fragmented healthcare system exac...

En este documento se plasma la evaluación de la eficacia y seguridad del uso del producto farmacéutico L-asparaginasa E. coli pegilada en el tratamiento de pacientes con leucemia linfoblástica aguda que presentan hipersensibilidad a L-asparaginasa E. coli nativa, en el contexto de no disponibilidad de L-asparaginasa Erwinia; cuyos resultados sustentaron la aprobación del uso de esta tecnología sanitaria en EsSalud.